GlassScriptPhysician profile
Gabriel Uwaifo
NPI 1043267818
$10,981.24
in general payments reported to CMS, 2019-2025
23 companies · $4,251 in 2025
The $4,251 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,752 · 2020: $21.86 · 2021: $48.43 · 2022: $43.29 · 2023: $2,608 · 2024: $257 · 2025: $4,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,396 · Food and Beverage: $1,594 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,396.06 |
| Food and Beverage | $1,594.35 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $3,965.43 | 2023-2025 | |
| Corcept Therapeutics | $3,695.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,305.56 | 2023 | |
| Alexion Pharmaceuticals, INC. | $1,125.00 | 2025 | Strensiq |
| Lilly USA, LLC | $221.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.27 | 2025 | |
| Novo Nordisk INC | $90.16 | 2019-2024 | |
| Sequel Med Tech, LLC | $89.83 | 2025 | Twiist |
| Dexcom, INC. | $80.31 | 2021-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $50.00 | 2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $45.15 | 2022-2024 | |
| Amryt Pharma Holdings LTD | $31.37 | 2023 | Mycapssa |
| Astellas Pharma US INC | $25.00 | 2023 | Veozah |
| Radius Health, INC. | $23.43 | 2024 | Tymlos |
| Grt US Holding, INC. | $22.74 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $21.86 | 2020 | |
| Nevro Corp. | $19.56 | 2022 | |
| Amgen INC. | $17.96 | 2024 | Evenity |
| Shire North American Group INC | $14.21 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Uwaifo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.